Dr. Staskin discusses counseling patients on vibegron for OAB

“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.

In this video, David Staskin, MD, discusses the takeaways associated with the findings from the study, “Vibegron for the treatment of patients with dry overactive bladder: A subgroup analysis from the EMPOWUR trial,” presented at the 2021 American Urological Association annual meeting. Staskin is a director of the Center for Male and Female Pelvic Health and associate professor of urology at Tufts University, Boston, Massachusetts.

Related Videos
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Patient predictors of postprostatectomy incontinence | Image credit: © jakkapan - stock.adobe.com
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Dr. Woodburn in an interview with Urology Times
Sarah Hecht, MD, answers a question during a Zoom interview
Ruchika Talwar, MD, answers a question during a Zoom video interview
hospital corridor
Joshua A. Halpern, MD, MS, answers a question during a Zoom video interview
Illustration of kidney cancer
Related Content
© 2023 MJH Life Sciences

All rights reserved.